Rakuten Investment Management Inc. Invests $566,000 in Kenvue Inc. $KVUE

Rakuten Investment Management Inc. bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 34,850 shares of the company’s stock, valued at approximately $566,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new position in Kenvue during the third quarter valued at $25,000. NBT Bank N A NY raised its position in shares of Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares during the last quarter. Trust Co. of Vermont lifted its stake in Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares in the last quarter. New England Capital Financial Advisors LLC boosted its holdings in Kenvue by 81.4% in the 3rd quarter. New England Capital Financial Advisors LLC now owns 2,563 shares of the company’s stock worth $42,000 after buying an additional 1,150 shares during the last quarter. Finally, Future Financial Wealth Managment LLC acquired a new stake in Kenvue in the 3rd quarter worth about $49,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity at Kenvue

In other Kenvue news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.68% of the company’s stock.

Kenvue Stock Up 0.4%

Shares of KVUE opened at $17.82 on Friday. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock has a fifty day simple moving average of $17.05 and a two-hundred day simple moving average of $18.15. The company has a market capitalization of $34.14 billion, a PE ratio of 23.76 and a beta of 0.60.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. During the same quarter in the prior year, the firm posted $0.28 earnings per share. Kenvue’s quarterly revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Analysts Set New Price Targets

KVUE has been the topic of several research reports. UBS Group decreased their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 8th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Finally, Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $20.23.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.